Expertise in
1
conditions

Isabel Blancas

Granada, AN, ES 
Expertise in
1
conditions
Granada, AN, ES 

Overview

Isabel Blancas practices practicing medicine in Granada, Spain.

Ms. Blancas is highly rated in 1 condition, according to our data. Her clinical expertise encompasses Breast Cancer, Diarrhea, Menopause, and Autosomal Recessive Hypotrichosis.

She is actively involved in clinical research, co-authoring 49 peer reviewed articles and participating in 7 clinical trials.

Gender

Female

Locations

Granada, AN, Spain
Other Locations
San Sebastian De Los Reyes, MD, Spain
Madrid, MD, Spain
Valencia, VC, Spain

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

EMBER-3: A Phase 3, Randomized, Open-Label Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Patients With Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With Endocrine Therapy
EMBER-3: A Phase 3, Randomized, Open-Label Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Patients With Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With Endocrine Therapy
Enrollment Status: Active_not_recruiting
Publish Date: July 22, 2026
Intervention Type: Drug
Study Drugs: Imlunestrant, Exemestane, Fulvestrant, Abemaciclib
Study Phase: Phase 3
Chemotherapy-Free pCR-Guided Strategy With Subcutaneous Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Cancer (PHERGAIN-2)
Chemotherapy-Free pCR-Guided Strategy With Subcutaneous Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Cancer (PHERGAIN-2)
Enrollment Status: Active_not_recruiting
Publish Date: April 29, 2026
Intervention Type: Drug
Study Drugs: Trastuzumab, Pertuzumab
Study Phase: Phase 2
A Phase II With 2 Parallel Cohorts Clinical Trial Targeting Estrogen Receptor Negative or PAM50 Non-luminal Disease With Atezolizumab in Combination With Trastuzumab and Vinorelbine in HER2-positive Advanced/Metastatic Breast Cancer - ATREZZO Study
A Phase II With 2 Parallel Cohorts Clinical Trial Targeting Estrogen Receptor Negative or PAM50 Non-luminal Disease With Atezolizumab in Combination With Trastuzumab and Vinorelbine in HER2-positive Advanced/Metastatic Breast Cancer - ATREZZO Study
Enrollment Status: Active_not_recruiting
Publish Date: September 09, 2025
Intervention Type: Drug
Study Drug: Atezolizumab+Trastuzumab+Vinorelbine
Study Phase: Phase 2
Named Patient Use Program to Provide Abemaciclib for the Treatment of Metastatic Breast Cancer
Named Patient Use Program to Provide Abemaciclib for the Treatment of Metastatic Breast Cancer
Enrollment Status: Approved_for_marketing
Publish Date: December 16, 2024
Intervention Type: Drug
A Phase II Trial of Palbociclib in Combination With Trastuzumab and Endocrine Therapy in Patients With Previously-treated Locally Advanced or Metastatic HER2-positive Breast Cancer (PATRICIA II)
A Phase II Trial of Palbociclib in Combination With Trastuzumab and Endocrine Therapy in Patients With Previously-treated Locally Advanced or Metastatic HER2-positive Breast Cancer (PATRICIA II)
Enrollment Status: Completed
Publish Date: April 18, 2024
Intervention Type: Drug
Study Drugs: Palbociclib, Trastuzumab, Endocrine therapy, Chemotherapy, Antibody-Drug Conjugates
Study Phase: Phase 2
Evaluation of Degree of Conversion of HER2 Receptor Between Primary Breast Cancer and Metastasis
Evaluation of Degree of Conversion of HER2 Receptor Between Primary Breast Cancer and Metastasis
Enrollment Status: Completed
Publish Date: March 10, 2023
Targeting EGFR/ERBB2 With Neratinib in Hormone Receptor (HR)-Positive/HER2-negative HER2-enriched Advanced/Metastatic Breast Cancer
Targeting EGFR/ERBB2 With Neratinib in Hormone Receptor (HR)-Positive/HER2-negative HER2-enriched Advanced/Metastatic Breast Cancer
Enrollment Status: Terminated
Publish Date: October 25, 2022
Intervention Type: Drug
Study Drug: Neratinib+Endocrine Therapy
Study Phase: Phase 2
View 6 Less Clinical Trials

49 Total Publications

Circulating immune and biochemical markers predict tumor response to immunotherapy in advanced melanoma and lung cancer.
Circulating immune and biochemical markers predict tumor response to immunotherapy in advanced melanoma and lung cancer.
Journal: Frontiers in immunology
Published: April 13, 2026

Frequently Asked Questions about Isabel Blancas

Is Isabel Blancas a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Isabel Blancas is classified as an Distinguished expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Isabel Blancas participate in research or clinical trials?

Yes. Isabel Blancas has published 49 articles and abstracts on conditions like Breast Cancer. You can view a list of Isabel Blancas's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Blancas's expertise for a condition
ConditionClose
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile